Overview
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
Status:
Completed
Completed
Trial end date:
2013-11-27
2013-11-27
Target enrollment:
Participant gender: